Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in Human Study of CT-1500 in Healthy Subjects
NCT05070702Phase 1Completed
- Sponsor
- Circadian Therapeutics
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CT-1500 in Non-24-hour sleep-wake disorder (N24SWD) (4 arms), sponsored by Circadian Therapeutics. Primary endpoints: Adverse Events and Serious Adverse Events, Change from baseline in Heart Rate and 4 more. Started Nov 2021; status: completed.
02
Drugs
CT-1500
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on NCT05070702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070702.